Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory? - Wikidata - awgldk - TriplyDB

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?

http://www.wikidata.org/entity/Q37941886

about

Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives An expanding role for interleukin-1 blockade from gout to cancer.Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Treating inflammation by blocking interleukin-1 in humans.

P2860

Q35133812-AC624627-7715-439D-82A6-BDB8BA2717B8 Q35219001-FAA5294B-7C38-4B9C-95C0-C345446DBA76 Q36816872-E0DAA1C4-BC54-48C1-96CA-DBBE7EB47C3D Q37636664-1D459C36-C373-46C2-8A9E-5616FA39849E

P2860

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?

http://www.wikidata.org/entity/Q37941886

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@en

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@nl

type

label

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@en

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@nl

prefLabel

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@en

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@nl

P1433

Q37941886-3E33161A-3932-4FBF-BBA2-696607A6FBEC

P1476

Q37941886-43006C04-C0AD-4288-8452-8C6E4EFBAC03

P2093

Q37941886-06FF577F-1A7F-43C0-981C-3EE8055E506A

Q37941886-16EA725B-F6DE-4618-9D60-21B3EEF52966

Q37941886-379C703D-934E-4732-BD28-57D667349915

P2860

Q37941886-252A0657-6144-4C2E-9DE8-F2D12EB029CA

Q37941886-46D71A86-835E-4802-91BD-2DF7D637AAA1

Q37941886-4D9AE261-ABD5-45E0-9E83-35FC9BF35511

Q37941886-4F5076E6-4CA0-424A-B6D4-060E806471DE

Q37941886-6D0F4B55-E4F9-43FD-A9A6-B55ECF2A8DD9

Q37941886-81D32F49-BA6D-482B-97A8-DA9540782AF6

Q37941886-9659CB7E-A5C0-441D-9D4D-24AAFC1C5EB3

Q37941886-982239B6-CDBD-46FC-9ED8-A09677181127

Q37941886-A267DF47-5715-48E8-ACA5-E15A84E62B88

Q37941886-AB657227-62B7-421F-A4C3-4984F63FF8BE

P304

Q37941886-A464AA26-6557-4ABD-993A-331AC051BF7B

P31

Q37941886-08763217-67A6-43D2-968B-39027CB87297

P356

Q37941886-D509B1BA-D251-40E3-9072-CD6B9BC351EE

P433

Q37941886-34A581D0-2618-4190-9AC9-83EF82CA35BA

P478

Q37941886-BD88A760-D9D8-42CD-BD1E-0D47A550121C

P577

Q37941886-51D4C62D-EC18-4AD1-9B5E-D68B07371DCE

P698

Q37941886-C472F2C9-6F17-4C3A-895B-9CA74A366920

P356

P1433

P1476

Muckle-Wells syndrome effectiv ...... ded dosing schedule mandatory?

@en

P2093

Peter Haeusermann

http://www.w3.org/2001/XMLSchema#string

Peter Itin

http://www.w3.org/2001/XMLSchema#string

Simon M Mueller

http://www.w3.org/2001/XMLSchema#string

P2860

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference.

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

Natural history and outcome in systemic AA amyloidosis.

Use of canakinumab in the cryopyrin-associated periodic syndrome.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Hereditary periodic fever and reactive amyloidosis.

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

P304

113-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000331580

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

223

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21967869

http://www.w3.org/2001/XMLSchema#string